tiprankstipranks
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
US Market
MLTX
MoonLake Immunotherapeutics
RESEARCH TOOLSreports
Want to see MLTX full AI Analyst Report?

MoonLake Immunotherapeutics (MLTX) Stock News & Sentiment

647 Followers
Buy Rating on MoonLake: Sonelokimab’s Differentiated IL‑17 Profile and Late‑Stage HS Opportunity Support $40 Target
Premium
Ratings
Buy Rating on MoonLake: Sonelokimab’s Differentiated IL‑17 Profile and Late‑Stage HS Opportunity Support $40 Target
13d ago
MLTX
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics
Premium
Ratings
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics
14d ago
MLTX
MoonLake Buy Rating: Clear HS Approval Path, Priority Review Upside, and Underappreciated Multi-Indication Value
Premium
Ratings
MoonLake Buy Rating: Clear HS Approval Path, Priority Review Upside, and Underappreciated Multi-Indication Value
20d ago
MLTX
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
Premium
Ratings
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
2M ago
MLTX
Sonelokimab: Strong HS and AxSpA Data, Clear Regulatory Path Support Best‑in‑Class Potential and Buy Rating
Premium
Ratings
Sonelokimab: Strong HS and AxSpA Data, Clear Regulatory Path Support Best‑in‑Class Potential and Buy Rating
2M ago
MLTX
MoonLake Highlights Positive S-OLARIS Data and Investor Day
Premium
Company Announcements
MoonLake Highlights Positive S-OLARIS Data and Investor Day
2M ago
8K
MLTX
MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target
Premium
Ratings
MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target
3M ago
MLTX
More MLTX News >

MLTX News on the Web

The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
The Motley Fool
Bearish
Insider Sell: Matthias Bodenstedt Sells Shares of MoonLake Immunotherapeutics (MLTX)
GuruFocus News
Neutral
Buy Rating on MoonLake: Sonelokimab’s Differentiated IL‑17 Profile and Late‑Stage HS Opportunity Support $40 Target
TipRanks News
Neutral
Major Insider Move at MoonLake Immunotherapeutics Stirs Investor Attention
TipRanks News
Neutral
Insider Sell: CEO Santos da Silva Jorge Sells 150,000 Shares of MoonLake Immunotherapeutics (MLTX)
GuruFocus News
Bearish
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics
TipRanks News
Bullish
MoonLake Buy Rating: Clear HS Approval Path, Priority Review Upside, and Underappreciated Multi-Indication Value
TipRanks News
Bullish
Major Insider Move at MoonLake Immunotherapeutics Shakes Up Investor Sentiment
TipRanks News
Neutral

News Score - Last 7 Days

Negative
MLTX
Sector Average
Media Buzz
This Week6 articles
Weekly Average4 articles
News Sentiment
This Week33%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MLTX’s Media Buzz Sentiment?
6 articles about MLTX were published this week. In an average week, 4 articles are published.
    What is MLTX’s weekly average amount of articles?
    In an average week, 4 articles about MLTX are published.
      What is MLTX’s News Sentiment?
      33% of articles about MLTX were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week